Paper Details

  1. Home
  2. Paper Details

Erythromycin ethylsuccinate, base and acistrate in the treatment of upper respiratory tract infection: two comparative studies of tolerability.

Author: AllonenH, ElonenE, RoosL, SalorantaP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Erythromycin ethylsuccinate was found to be better tolerated than erythromycin base in patients with upper respiratory tract infections. Both were effective in treating the infection.
Paper Details　
Original Abstract of the Article :
The efficacy and tolerability of erythromycin ethylsuccinate, erythromycin base and erythromycin acistrate were studied in two separate randomized studies in 80 and 82 primary health care patients with upper respiratory tract infections. In Study I, the patients were given either ethylsuccinate 666 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/24.3.455

データ提供：米国国立医学図書館（NLM）

Comparing Tolerability of Different Erythromycin Formulations

This research delves into the world of infectious disease management, focusing on the tolerability of different erythromycin formulations used to treat upper respiratory tract infections. Imagine a patient, battling a cough and sore throat, seeking relief from erythromycin. This research aims to identify the most tolerable form of this antibiotic, ensuring optimal patient comfort.

The study compared the tolerability of three erythromycin formulations: ethylsuccinate, base, and acistrate. The researchers conducted two randomized studies, meticulously recording and analyzing the occurrence of common side effects like abdominal pain, nausea, diarrhea, and vomiting. Their findings revealed significant differences in the tolerability profiles of these formulations.

The study found that erythromycin ethylsuccinate caused significantly less abdominal pain compared to the base form, while there was no significant difference in tolerability between ethylsuccinate and acistrate. These findings provide valuable insights for clinicians when choosing the most tolerable erythromycin formulation for their patients.

Navigating the Terrain of Antibiotic Therapy

This research serves as a guide for navigating the terrain of antibiotic therapy. It emphasizes the importance of considering the tolerability profiles of different formulations, particularly when choosing medications for common infections. By selecting the most tolerable formulation, healthcare providers can optimize patient comfort and adherence to treatment.

Dr. Camel's Conclusion

This research highlights the importance of considering the individual needs of patients, especially when it comes to medication choices. The study's findings can guide clinicians in selecting the most tolerable erythromycin formulation for their patients, potentially reducing discomfort and improving treatment adherence. The goal is to ensure that patients receive the best possible care while minimizing the burden of side effects.

Date :
  1. Date Completed 1989-12-05
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

2808197

DOI: Digital Object Identifier

10.1093/jac/24.3.455

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.